Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

RE-104

From Wikipedia, the free encyclopedia
(Redirected from4-GO-DiPT)
Chemical compound

Pharmaceutical compound
RE-104
Clinical data
Other namesRE-104; RE104; 4-Glutaryloxy-N,N-diisopropyltryptamine; 4-Hydroxy-N,N-diisopropyltryptamineO-glutarate;O-Glutaryl-4-hydroxy-N,N-diisopropyltryptamine; 4-HO-DiPT glutarate;O-Glutaryl-4-HO-DiPT; 4-GO-DiPT
Legal status
Legal status
  • Investigational
Pharmacokinetic data
Eliminationhalf-life3-4 hours hours[1]
Identifiers
  • 1-[3-[2-[Bis(1-methylethyl)amino]ethyl]-1H-indol-4-yl] pentanedioate
CAS Number
PubChemCID
UNII
Chemical and physical data
FormulaC21H30N2O
Molar mass326.484 g·mol−1
3D model (JSmol)
  • CC(C)N(CCC1=CNC2=C1C(=CC=C2)OC(=O)CCCC(=O)O)C(C)C
  • InChI=1S/C21H30N2O4/c1-14(2)23(15(3)4)12-11-16-13-22-17-7-5-8-18(21(16)17)27-20(26)10-6-9-19(24)25/h5,7-8,13-15,22H,6,9-12H2,1-4H3,(H,24,25)
  • Key:LSDOIAGGRBGDJJ-UHFFFAOYSA-N

RE104, formerly known asFT-104, and as4-glutaryloxy-N,N-diisopropyltryptamine (4-HO-DiPTO-glutarate or4-GO-DiPT), is an investigational drug product being developed by the pharmaceutical companyReunion Neuroscience.[2] RE104 aprodrugester of a syntheticpsychedelic4-hydroxytryptamine,4-HO-DiPT.[3] It is one of a number of related psychedelic derivatives being developed as pharmaceuticals to treat mood disorders.

RE104 is in humanclinical trials as a possible treatment forpostpartum depression andtreatment-resistant depression.[4][5][6][7] As of 2024, RE104 entered a Phase II clinical trial for post-partum depression.[8]

Pharmacology

[edit]

RE104 is aprodrug that is converted into thepsychedelictryptamine4-HO-DiPT upon administration.[3][9] 4-OH-DiPT schemically related to theneurotransmitterserotonin and acts as anon-selectiveagonist of theserotonin receptors. 4-OH-DiPT acts as anagonist on theserotonin 2A receptor (Ki 120 nM).[3] Activation of one serotonin receptor, the serotonin5-HT2A receptor, is specifically responsible for the hallucinogenic effects and preclinical behavioral changes induced by4-OH-DiPT and otherserotonergic psychedelics.

Research

[edit]

Synthesis, pharmacology and preclinical studies with RE104 have been published.[3] 4-OH-DiPT, the active metabolite of RE104, produces measurablehead-twitch response in rodents, indicative of its psychedelic properties.[10] Discriminative stimulus tests in rats showed 4-OH-DiPT fully substituted for DOM with a 5-fold lower potency than DOM and 2-fold lower potency than psilocin.[11] Findings suggest that 4-OH-DiPT activates BLA interneurons via the 5-HT2A receptor to enhance GABAergic inhibition of BLA principal neurons in the basolateral amygdala, which provides a potential mechanism for suppressing learned fear (fear extinction).[12]

RE104 is being developed as a subcutaneous injection. RE104 has been investigated in a randomized, placebo-controlled, single escalating dose Phase 1 study in healthy volunteers to assess the safety of RE104, as well as to characterize the pharmacodynamics, including the duration and intensity of the psychedelic experience.[13] The meanduration of the psychedelic experience after administration of RE104 30 mg in humans was found to be 3.7 hours.[1]

RE104 is currently under investigation to treatpostpartum depression (PPD).[1][14][15]

See also

[edit]

References

[edit]
  1. ^abcPollack M, Hocevar-Trnka J, Bryson N, Taylor B, Johnson M, Alexander R (December 2024)."ACNP 63rd Annual Meeting: Poster Abstracts P609-P914: P697. RE104: A Novel, Shorter-Acting Psychedelic for Post Partum Depression".Neuropsychopharmacology.49 (Suppl 1): 418–594 (469–470).doi:10.1038/s41386-024-02013-y.PMID 39643635.
  2. ^Braner S (May 8, 2024)."Reunion Neuroscience raises $103 million for a psychedelic to treat depression".Chemical & Engineering News.
  3. ^abcdBryson N, Alexander R, Asnis-Alibozek A, Ehlers MD (June 2024)."RE104: Synthesis and Activity of a Novel Serotonergic Psychedelic Prodrug of 4-Hydroxy-N,N-diisopropyltryptamine".ACS Chemical Neuroscience.15 (12):2386–2395.doi:10.1021/acschemneuro.4c00058.PMC 11191588.PMID 38758589.
  4. ^Hallifax J (11 August 2022)."An Inside Look into Field Trip's Next-Generation Psychedelic, FT-104".
  5. ^WO 2022/000091, Bryson N, "Tryptamine prodrugs", published 6 January 2022, assigned to Field Trip Psychedelics Inc. 
  6. ^US 2022/0024956, Slassi A, Araujo J, "Psilocin derivatives as serotonergic psychedelic agents for the treatment of CNS disorders.", published 27 January 2022, assigned to Mindset Pharma Inc. 
  7. ^WO 2022/246572, Slassi A, Araujo J, Higgin GH, Gabriele J, "Hallucinogen-Fatty Acid Combination", published 1 December 2022, assigned to Mindset Pharma Inc. 
  8. ^Alexander R, Hocevar-Trnka J (June 26, 2024)."RE104: A Novel, Fast-Acting Psychedelic for Postpartum Depression".psychiatrictimes.com.
  9. ^"Reunion Neuroscience Announces Publication of Results from Early Preclinical Studies Demonstrating the Potential of RE104 for Development in Depressive Disorders". GlobalNewswire. May 20, 2024 – via Yahoo!Finance.
  10. ^Klein AK, Chatha M, Laskowski LJ, Anderson EI, Brandt SD, Chapman SJ, et al. (April 2021)."Investigation of the Structure-Activity Relationships of Psilocybin Analogues".ACS Pharmacology & Translational Science.4 (2):533–542.doi:10.1021/acsptsci.0c00176.PMC 8033608.PMID 33860183.
  11. ^Gatch MB, Hoch A, Carbonaro TM (April 2021)."Discriminative Stimulus Effects of Substituted Tryptamines in Rats".ACS Pharmacology & Translational Science.4 (2):467–471.doi:10.1021/acsptsci.0c00173.PMC 8033599.PMID 33860176.
  12. ^Kelly TJ, Bonniwell EM, Mu L, Liu X, Hu Y, Friedman V, et al. (April 2024)."Psilocybin analog 4-OH-DiPT enhances fear extinction and GABAergic inhibition of principal neurons in the basolateral amygdala".Neuropsychopharmacology.49 (5):854–863.doi:10.1038/s41386-023-01744-8.PMC 10948882.PMID 37752222.
  13. ^"ANZCTR - Registration".www.anzctr.org.au. Retrieved2025-03-26.
  14. ^Reunion Neuroscience Inc (2025-03-06).A Multicenter, Randomized, Double-Blind, Parallel-Group Dose-Controlled Study Evaluating the Safety and Efficacy of RE104 for Injection in the Treatment of Patients With Postpartum Depression (PPD) (Report). clinicaltrials.gov.
  15. ^Reunion Neuroscience Inc (2025-03-06).A Multicenter, Randomized, Double-Blind, Parallel-Group Dose-Controlled Study Evaluating the Safety and Efficacy of RE104 for Injection in the Treatment of Patients With Postpartum Depression (PPD) (Report). clinicaltrials.gov.
Tryptamines
No ring subs.
4-Hydroxytryptamines
5-Hydroxytryptamines
5-Methoxytryptamines
Other ring subs.
α-Alkyltryptamines
Others
Cyclized
Bioisosteres
Phenethylamines
Scalines
2C-x
3C-x
DOx
4C-x
MDxx
FLY
25x-NB (NBOMes)
Others
Cyclized
Lysergamides
Others
Natural sources
5-HT1
5-HT1A
5-HT1B
5-HT1D
5-HT1E
5-HT1F
5-HT2
5-HT2A
5-HT2B
5-HT2C
5-HT37
5-HT3
5-HT4
5-HT5A
5-HT6
5-HT7
Tryptamines
4-Hydroxytryptamines
andesters/ethers
5-Hydroxy- and
5-methoxytryptamines
N-Acetyltryptamines
α-Alkyltryptamines
Triptans
Cyclized tryptamines
Isotryptamines
Related compounds
Retrieved from "https://en.wikipedia.org/w/index.php?title=RE-104&oldid=1284992388"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp